Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 160NIH 30NETWORK 17INDUSTRY 7OTHER_GOV 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 5Multiple Myeloma 3Leukemia 3Burkitt Lymphoma 3Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Solid Tumors 1Solid Tumor 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms by Site 1Nasopharyngeal Carcinoma 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Hodgkin Disease 1Hematopoietic System--Cancer 1Hematologic Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Disease Progression 1

Interventions

fludarabine 3Cyclophosphamide 3fludarabine phosphate 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Burkitt Lymphoma × Cyclophosphamide × Clear all
NCT06056752 2023-10-24

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Anhui Provincial Hospital

Phase 1 Recruiting
10 enrolled
Lymphoid

Burkitt Lymphoma

NCT02924753 2017-12-29

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Henan Cancer Hospital

Phase 1 Unknown
20 enrolled
Lymphoid

Burkitt Lymphoma

NCT03263208 2017-10-20

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Henan Cancer Hospital

Phase 1/2 Unknown
20 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡